Bristol Myers Squibb to Present Phase 2 Pumitamig Lung Cancer Data at ESMO 2026

Bitget2026/10/19 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bristol Myers Squibb will present cancer trial data at ESMO 2026 in Madrid, October 23-27, including two late-breaking Phase 3 iza-bren studies.
Iza-bren presentations will cover previously treated breast cancer and EGFR-mutant lung cancer; Biokin sponsored both Phase 3 trials.
Pumitamig, jointly developed with BioNTech, will feature in late-breaking global Phase 2 findings evaluating treatment for metastatic lung cancer.
Final overall survival results from CheckMate 8HW will compare Opdivo with Yervoy against Opdivo alone or chemotherapy in metastatic colorectal cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261016505356) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bristol Myers Squibb to Present Phase 2 Pumitamig Lung Cancer Data at ESMO 2026

You may also like

Crypto prices